Upcoming Earnings: Q3 '26
Estimated EPS
-$0.08
Estimated Rev
---
$AVXL Q1 '26 Earnings Results & Recap Anavex anticipates, at its current cash utilization rate, an approximate cash runway of more than 3 years, supporting its ongoing clinical pipeline development.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.08 | -- | -- | N/A |
Q2 '26 | -$0.07 | -$0.06 | 14.29% | BEAT |
Q1 '26 | -$0.12 | -$0.06 | 51.35% | BEAT |
Q4 '25 | -$0.15 | -$0.11 | 26.67% | BEAT |
Q3 '25 | -$0.14 | -$0.16 | -12.41% | MISSED |